Alexis Ogdie-Beatty, MD, MSCE

Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Director, Penn Psoriatic Arthritis Clinic, University of Pennsylvania, Philadelphia, PA
Worker Without Compensation (WOC), Philadelphia VA Medical Center, University of Pennsylvania, Philadelphia, PA
Senior Scholar, Penn Center for Clinical Epidemiology and Biostatistics
Director, Penn Center for Clinical Epidemiology and Biostatistics
Department: Medicine
Graduate Group Affiliations
Contact information
3400 Spruce Street
5 White Building
Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283
5 White Building
Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283
Office: 215-662-2454
Fax: 215-662-4500
Fax: 215-662-4500
Education:
BS
University of Minnesota, 2002.
MD
Georgetown University School of Medicine, 2006.
MSCE
University of Pennsylvania, 2012.
Permanent linkBS
University of Minnesota, 2002.
MD
Georgetown University School of Medicine, 2006.
MSCE
University of Pennsylvania, 2012.
Description of Clinical Expertise
Psoriatic Arthritis, Ankylosing Spondylitis, Spondyloarthropathies, Other Inflammatory Arthritis (e.g. Rheumatoid Arthritis)Description of Research Expertise
Psoriatic Arthritis, Axial Spondyloarthritis, Epidemiology, PharmacoepidemiologySelected Publications
Walsh JA, Ogdie A, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Dalby CM, Chakravarty SD, Dennis N, Gossec L.: Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe. Joint Bone Spine Jan 2023.Kumthekar A, Pedro S, Michaud K, Ozen G, Katz P, Baker J, Ogdie A.: Physical activity habits among older adults living with rheumatic disease. J Rheumatol Jan 2023.
Tillett W, Ogdie A, Passey A, Gorecki P.: Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study. RMD Open 2023.
Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, Uddin Z, Hu J, Castillo R, Gong C, Qian K, Piguet V, Tausk F, Yeung J, Neimann AL, Gulliver W, Thiele RG, Merola JF, Ogdie A, Rahman P, Chakravarty SD, Eder L, Ritchlin CT, Scher JU.: Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open 12: e063650, Dec 2022.
Ogdie A, Hwang M, Pedro S, Veeranki P, Yi E, Hass S, Michaud K.: Association between disability scores and opioid use in patients with psoriatic arthritis and ankylosing spondylitis. Rheumatology (Oxford) Dec 2022.
Bergman MJ, Zueger P, Patel J, Saffore CD, Topuria I, Cavanaugh C, Fang S, Clewell J, Ogdie A.: Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry. Rheumatol Ther Nov 2022.
Mease PJ, Ogdie A, Chakravarty SD, Shiff NJ, Lin I, McLean RR, Malley W, Spitzer RL, Kavanaugh A, Merola JF.: Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Drugs Real World Outcomes Oct 2022.
Ogdie A, Maksabedian Hernandez EJ, Shaw Y, Stolshek B, Michaud K.: Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis. ACR Open Rheumatol Aug 2022.
Ogdie A, Harrison RW, McLean RR, Lin TC, Lebwohl M, Strober BE, Zhuo J, Patel V, Mease PJ.: Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. J Am Acad Dermatol Aug 2022.
Gossec L, Walsh JA, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Chakravarty SD, Ogdie A.: Women with Psoriatic Arthritis Experience Higher Disease Burden than Men: Findings from a Real-World Survey in the USA and Europe. J Rheumatol Aug 2022.